Literature DB >> 21736657

Atrial electrical and structural changes associated with longstanding hypertension in humans: implications for the substrate for atrial fibrillation.

Caroline Medi1, Jonathan M Kalman, Steven J Spence, Andrew W Teh, Geoffrey Lee, Ilona Bader, David M Kaye, Peter M Kistler.   

Abstract

INTRODUCTION: Hypertension (HT) is the most common modifiable risk factor for atrial fibrillation (AF), yet little is known of the atrial effects of chronic HT in humans. We aimed to characterize the electrophysiologic (EP) and electroanatomic (EA) remodeling of the right atrium (RA) in patients with chronically treated systemic HT and left ventricular hypertrophy (LVH) without a history of AF. METHODS AND
RESULTS: Twenty patients with (systolic BP 145 ± 10 mmHg) and without (BP 119 ± 11 mmHg, P < 0.01) systemic HT underwent detailed conventional EP and EA voltage and activation mapping. We measured RA refractoriness at the coronary sinus and high septum at cycle lengths (CLs) 600 and 450 ms, and RA conduction velocities, activation times, and voltages at a global and regional level at CLs 600 ms and 300 ms. HT was associated with slowing of global (73 ± 17 cm/s vs 96 ± 12 cm/s in controls, P < 0.01) and regional conduction velocity particularly in the posterior RA (70 ± 17 cm/s vs 96 ± 12 cm/s in controls, P < 0.01) at the crista terminalis (fractionation and double potentials in HT 72%± 4 vs 43%± 23 in controls, P = 0.04). Mean RA voltage was similar between the 2 groups, however HT was associated with an increase in areas of low voltage (<0.5 mV; HT 13% vs controls 9%, P = 0.04). Sustained AF was induced in 30% HT patients and no controls.
CONCLUSION: Chronically treated systemic HT with LVH is accompanied by atrial remodeling characterized by: (i) global conduction slowing, (ii) regional conduction delay particularly at the crista terminalis, and (iii) increased AF inducibility. These changes may in part be responsible for the increased propensity to AF associated with systemic HT.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21736657     DOI: 10.1111/j.1540-8167.2011.02125.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  35 in total

1.  Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.

Authors:  Vibhu Parcha; Nirav Patel; Rajat Kalra; Joonseok Kim; Orlando M Gutiérrez; Garima Arora; Pankaj Arora
Journal:  Hypertension       Date:  2020-05-04       Impact factor: 10.190

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 3.  The Impact of Diet and Lifestyle on Atrial Fibrillation.

Authors:  Chrishan J Nalliah; Prashanthan Sanders; Jonathan M Kalman
Journal:  Curr Cardiol Rep       Date:  2018-10-12       Impact factor: 2.931

Review 4.  Impact of Metabolic Syndrome on Ablation-Outcome in Patients with Atrial Fibrillation: A Systematic Review.

Authors:  Sanghamitra Mohanty; Luigi Di Biase; Prasant Mohanty; Pasquale Santangeli; Bai Rong; Trivedy Chintan; David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Shane Bailey; Jason Zagrodzky; Andrea Natale
Journal:  J Atr Fibrillation       Date:  2013-02-12

Review 5.  Atrial Fibrillation and Metabolic Syndrome: Understanding the Connection.

Authors:  Prabhat Kumar; Anil K Gehi
Journal:  J Atr Fibrillation       Date:  2012-10-06

6.  Predictors of non-pulmonary vein foci in paroxysmal atrial fibrillation.

Authors:  Keita Watanabe; Junichi Nitta; Osamu Inaba; Akira Sato; Yukihiro Inamura; Nobutaka Kato; Masahito Suzuki; Masahiko Goya; Kenzo Hirao; Tetsuo Sasano
Journal:  J Interv Card Electrophysiol       Date:  2020-05-28       Impact factor: 1.900

Review 7.  Ablation of long-standing persistent atrial fibrillation.

Authors:  Behram P Mody; Anoshia Raza; Jason Jacobson; Sei Iwai; Daniel Frenkel; Rhadames Rojas; Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-08

8.  The effects of radio-frequency ablation on blood pressure control in patients with atrial fibrillation and hypertension.

Authors:  Alexies Ramirez; Christina F Pacchia; Natalie A Sanders; Stephen L Wasmund; Mohamed H Hamdan
Journal:  J Interv Card Electrophysiol       Date:  2012-08-11       Impact factor: 1.900

Review 9.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

10.  Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: Electrophysiologic substrates for atrial fibrillation.

Authors:  Tarek Zghaib; Esra Gucuk Ipek; Sohail Zahid; Muhammad Adnan Balouch; Satish Misra; Hiroshi Ashikaga; Ronald D Berger; Joseph E Marine; David D Spragg; Stefan L Zimmerman; Vadim Zipunnikov; Natalia Trayanova; Hugh Calkins; Saman Nazarian
Journal:  Heart Rhythm       Date:  2016-08-19       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.